Author:
Song Peng,Zhang Jingcheng,Shang Congcong,Zhang Li
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Zappa, C. & Mousa, S. A. Non-small cell lung cancer: current treatment and future advances. Transl. Lung Cancer Res. 5, 288 (2016).
2. Chen, W. et al. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians. 66, 115 (2016).
3. Yang, J. C. et al. Afatinib versus cisplatin-based chemotherapy for EGFRmutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survivaldata from two randomised, phase 3. trials. Lancet Oncology 16, 141 (2015).
4. Horn, L. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 35, 3924 (2017).
5. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New England. Journal of Medicine 373, 1627 (2015).
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献